<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1104233522
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARPEK 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        132.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>How ARPEK works</strong></u></p><p>It is taken to control epilepsy. Epilepsy is a condition where you have repeated seizures (fits). There are many different types of seizures, ranging from mild to severe. ARPEK belongs to a group of medicines called antiepileptics. These medicines are thought to work by controlling brain chemicals which send signals to nerves so that seizures do not happen.</p><p>This medicine may be used alone, or in combination with other medicines, to treat your condition. Your doctor may prescribe ARPEK in addition to your current therapy. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason. This medicine is available only with a doctor&rsquo;s prescription.</p><p>There is no evidence that this medicine is addictive.</p><p>&nbsp;</p><p><u><strong>What ARPEK is taken for</strong></u></p><ul><li>Treatment of partial onset seizures with or without secondary generalization in adults, children from 6 years of age with epilepsy.</li><li>Treatment myoclonic seizures in adults and adolescent from 12 years of age with juvenile Myoclonic.</li><li>Treatment of primary generalized tonic-clonic seizures in adults and children from 12 years of age with idiopathic Generalized Epilepsy.</li></ul><p>&nbsp;</p><p><strong>Use in children</strong></p><p>There is not enough information to recommend using this medicine in children less than 4 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>a- Do not take ARPEK&nbsp;</strong></u></p><p>- If it has passed the expiry date (EXP) printed on the pack.<br />- If the packaging is torn, shows signs of tampering or it does not look quite right.<br />- If you have had an allergic reaction to ARPEK or any of the ingredients listed at the end of this leaflet.</p><p>Symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body, itching or hives on the skin.</p><p><strong>If you think you are having an allergic reaction, contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.</strong></p><p>Symptoms of an allergic reaction may include some or all of the following:</p><p>&bull; cough, shortness of breath, wheezing or difficulty breathing<br />&bull; swelling of the face, lips, tongue, or other parts of the body<br />&bull; rash, itching or hives on the skin<br />&bull; fainting<br />&bull; hayfever-like symptoms.</p><p>&nbsp;</p><p><u><strong>b- Take special care with ARPEK</strong></u></p><p><strong>Before you start taking this medicine, tell your doctor:</strong></p><p>- If you have allergies to any other medicines, especially barbiturates or any other anticonvulsant medicines.<br />- If you have allergies to any other substances, such as foods, preservatives or dyes.<br />- If you have or have had any medical conditions, especially the following:<br />&bull; kidney problems (renal damage, renal insufficiency, impaired renal function)<br />&bull; liver problems.<br />- If you have recently been vaccinated or plan to get a vaccination.<br />- If you are planning to have surgery.<br />- If you are currently receiving or are planning to receive dental treatment.</p><p>&nbsp;</p><p><strong>While you are taking ARPEK</strong></p><p>Tell your doctor immediately:</p><p>&bull; &nbsp; If you notice an increase in seizures (fits)<br />&bull; &nbsp; If you have symptoms of depression or thoughts of self- harm.</p><p>Tell your doctor if you feel this medicine is not helping your condition. Your doctor may need to change your medicine.</p><p>Tell your doctor, if for any reason, you have not taken this medicine exactly as prescribed. Otherwise, your doctor may change your treatment unnecessarily.</p><p>Tell any other doctors, dentists and pharmacists who are treating you that you take this medicine.</p><p><strong>Be sure to keep all of your doctor&rsquo;s appointments so that your progress can be checked.</strong></p><p>Your doctor may occasionally do tests to make sure the medicine is working and to prevent side effects. Go to your doctor regularly for a check-up.</p><p>Do not give this medicine to anyone else, even if their symptoms seem similar to yours or they have the same condition as you.</p><p>Do not take your medicine to treat any other condition unless your doctor or pharmacist tells you to.</p><p>Do not stop taking your medicine, or change the dosage, without first checking with your doctor.</p><p>&nbsp;</p><p><u><strong>c- Taking ARPEK with other medicines, herbal or dietary supplements</strong></u></p><p>ARPEK does not interact with the oral contraceptive pill. However, you may be given ARPEK together with other antiepileptic drugs that do interact and they may compr omise contraceptive efficacy. Your doctor may advise you to use an additional method of contraception, if you take ARPEK with other antiepileptic drugs.</p><p>Inform your doctor if you are planning to take any other medicines, this includes vitamins and supplements that are available from your pharmacy, supermarket or health food shop.</p><p>&nbsp;</p><p><u><strong>d- Taking ARPEK with food and drink</strong></u></p><p>It may be taken with or without food.</p><p>&nbsp;</p><p><u><strong>e- Pregnancy and breast-feeding</strong></u></p><p>Do not take this medicine:</p><p>- If you are pregnant or intend to become pregnant, without talking to your doctor first.</p><p>Like most antiepileptic medicines, ARPEK is not recommended for use during pregnancy. However, it is very important to control your fits while you are pregnant. If it is necessary for you to take this medicine, your doctor can help you decide whether or not to take it during pregnancy.</p><p>- If you are breast-feeding or intend to breast-feed. ARPEK passes into breast milk.</p><p>&nbsp;</p><p><u><strong>f- Driving and using machines</strong></u></p><p><strong>Be careful when driving or operating machinery until you knows how this medicine affects you.</strong></p><p>As with other anticonvulsant medicines, ARPEK may cause drowsiness or affect alertness in some people. This is more frequent at the beginning of treatment or at dosage increase.</p><p>Make sure you know how you react to this medicine before you drive a car, operate machinery, or do anything else that could be dangerous if you are drowsy.</p><p>Children should not ride a bike, climb trees or do anything else that could be dangerous if they are feeling drowsy or sleepy.</p><p>Combining this medicine with alcohol can make you more drowsy. Your doctor may suggest you stop alcohol while you are being treated with ARPEK.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>How much ARPEK to take&nbsp;</strong></u></p><p>Follow carefully all directions given to you by your doctor or pharmacist. Their instructions may be different to the information in this leaflet.</p><p>For patients 12 years of age and older, the dosage is generally between 1000 mg and 3000 mg each day.</p><p>For children 4 to 11 years of age the dose is 20 mg/kg to 60 mg/kg each day.</p><p>There is no data to support the use of this medicine for patients less than 4 years of age.</p><p>Your doctor or pharmacist will tell you how much of this medicine you should take. This will depend on your condition and whether you are taking any other medicines.</p><p>Your doctor may recommend that you start with a low dose of ARPEK and slowly increase the dose to the lowest amount needed to control your epilepsy/seizures (fits).</p><p>Follow all directions given to you by your doctor carefully. They may differ from the information contained in this leaflet.</p><p>Do not stop taking your medicine or change your dosage without first checking with your doctor.</p><p>&nbsp;</p><p><u><strong>How and When to take ARPEK</strong></u></p><p>Swallow the tablets whole with a glass of water. This medicine must be taken two times a day, once in the morning and once in the evening, at about the same time each day.</p><p>Taking it at the same time each day will have the best effect and will also help you remember when to take it.</p><p>It does not matter if you take it before, with or after food.</p><p>Most anticonvulsant medicines take time to work, so do not be discouraged if you do not feel better straight away.</p><p>Continue taking your medicine for as long as your doctor tells you.</p><p>This medicine helps control your condition, but does not cure it. Therefore you must take your medicine every day, even if you feel well.</p><p>Make sure you have enough to last over weekends and holidays.</p><p><strong>Do not stop taking this medicine, or change the dosage, without checking with your doctor.</strong></p><p><strong>Stopping this medicine suddenly may cause unwanted effects or make your condition worse. Your doctor will slowly reduce your dose before you can stop taking it completely.</strong></p><p>&nbsp;</p><p><u><strong>a- If you take more ARPEK than should</strong></u></p><p><strong>If you think that you or anyone else may have taken too much of this medicine, immediately telephone your doctor or the Poisons Information Centre for advice. Alternatively go to the Accident and Emergency Department at your nearest hospital.</strong></p><p><strong>Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.</strong></p><p>If you take too much ARPEK, you may feel drowsy.</p><p>&nbsp;</p><p><u><strong>b- If you forget to take ARPEK</strong></u></p><p><strong>Contact your doctor if you have missed one or more doses.<br />Do not take a double dose to make up for missed doses.</strong></p><p>This may increase the chance of unwanted side effects.</p><p>If you are not sure what to do, ask your doctor or pharmacist.</p><p>If you have trouble remembering to take your medicine, ask your pharmacist for some hints.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking levetiracetam or if you have any questions or concerns. Do not be alarmed by the following lists of side effects. You may not experience any of them. All medicines can have side effects. Sometimes they are serious but most of the time they are not.&nbsp;</p><p>Tell your doctor or pharmacist if you notice any of the following and they worry you.</p><p><strong>Very Common (greater than or equal to 10%)</strong></p><p>&bull; Accidental Injury &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;<br />&bull; Asthenia&nbsp;<br />&bull; Headache &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;<br />&bull; Infection&nbsp;<br />&bull; Somnolence</p><p><strong>Common (greater than or equal to 1% and &lt; 10%)</strong></p><p>&bull; Abdominal Pain &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Back Pain<br />&bull; Chest Pain &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Fever&nbsp;<br />&bull; Flu Syndrome &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Hostility&nbsp;<br />&bull; Anorexia &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Diarrhoea&nbsp;<br />&bull; Dyspepsia &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Gastroententeritis&nbsp;<br />&bull; Gingivitis &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Nausea&nbsp;<br />&bull; Tooth Disorder &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Vomiting&nbsp;<br />&bull; Ecchymosis &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Weight Gain or weight loss<br />&bull; Amnesia &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Anxiety&nbsp;<br />&bull; Ataxia &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Convulsion<br />&bull; Depression &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Dizziness&nbsp;<br />&bull; Emotional Liability &nbsp;&nbsp; &nbsp;&bull; Insomnia&nbsp;<br />&bull; Nervousness &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Paresthesia&nbsp;<br />&bull; Thinking Abnormal &nbsp;&nbsp; &nbsp;&bull; Tremor&nbsp;<br />&bull; Vertigo &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Bronchitis&nbsp;<br />&bull; Cough Increased &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Pharyngitis&nbsp;<br />&bull; Rhinitis &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Sinusitis&nbsp;<br />&bull; Rash &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Amblyopia&nbsp;<br />&bull; Diplopia &nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; Otitis Media&nbsp;<br />&bull; Urinary Tract Infection &nbsp;&nbsp; &nbsp;&bull; Feeling tired, drowsy or sleepy<br />&bull; Common cold</p><p>Tell your doctor as soon as possible if you notice any of the following. These may be serious side effects. You may need medical attention:&nbsp;</p><p>&bull; mood changes such as depression, nervousness, aggression, anger, anxiety, confusion, hallucination and irritability<br />&bull; upper respiratory tract infections<br />&bull; weight loss.</p><p>If you experience any of the following, stop taking your medicine and contact your doctor immediately or go to the Accident and Emergency department at your nearest hospital. These are very serious side effects. You may need urgent medical attention or hospitalization.</p><p>&bull; thoughts of harming yourself<br />&bull; more frequent or more severe seizures.</p><p>Other side effects not listed above may occur in some patients.</p><p>Some of these side effects can only be found when your doctor does tests from time to time to check your progress.</p><p>Tell your doctor if you notice anything else that is making you feel unwell.</p><p><strong>If you experience more frequent or more severe seizures (fits), or thoughts of self-harm, tell your doctor immediately or go to the Accident and Emergency department at your nearest hospital.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine where children cannot reach it.<br />- Keep your medicine in its original packaging until it is time to take it.<br />- Keep your medicine in a cool dry place and store below 30&deg;C.<br />- Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.<br />- A locked cupboard at least one- and-a-half metres above the ground is a good place to store medicines.<br />- Disposal: If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, ask your pharmacist what to do with any medicine that is left over.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is Levetiracetam.</p><p>&bull; The other ingredients are copovidone, colloidal anhydrous silica, hypromellose, hydroxypropylcellulose, macrogol 8000, titanium dioxide, anhydrous citric acid, iron oxide yellow (500 mg &amp; 750 mg tablet only) and iron oxide red (750 mg tablet only).</p><p>This medicine is gluten-free, lactose-free, sucrose-free, tartrazine-free and other azo dyes-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                250 mg tablets:
White, oval, biconvex, film-coated tablets, engraved “LEV” score “250” on one side, “APO” on the other side. In blister packs of 60 tablets.

500 mg tablets:
Yellow, oval, biconvex, film- coated tablets, engraved “LEV” score “500” on one side, “APO” on the other side. In blister packs of 60 tablets.

750 mg tablets:
Orange, oval, biconvex, film- coated tablets, engraved “LEV” score “750” on one side, “APO” on the other side. In blister packs of 60 tablets. Also in bottles of 60, 100 and 500 tablets.

1000 mg tablets:
White, oval, biconvex, film-coated tablets, engraved “LEV” score “1000” on one side, “APO” on the other side. In blister packs of 60 tablets. Also in bottles of 60, 100 and 500 tablets.

* Not all pack types/strengths may be available.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Incorporated<br />150 Signet Drive<br />Toronto, Ontario<br />Canada, M9L 1T9<br />Tel: 1-800-268-4623, Fax: 1-800-609-9444<br />www.apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised 05/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><u><strong>كيف يعمل اربك</strong></u></p><p>يستخدم هذا العلاج للسيطرة على الصرع. والصرع هو حالة يعاني المصاب بها من نوبات متكررة (تشنجات). وهناك أنواع مختلفة من النوبات الصرعية تتراوح مابين الخفيفة والشديدة. ينتمي اربك إلى مجموعة من الأدوية تسمى مضادات الصرع. ويعتقد أن هذه الأدوية تعمل عن طريق تنظيم المواد الكيميائية في المخ والتي تقوم بدورها بإرسال إشارات إلى الأعصاب وبالتالي لا تحدث التشنجات.</p><p>قد يستخدم هذا الدواء وحده أو مع أدوية أخرى لعلاج حالتك. وقد يصف الطبيب اربك بالإضافة إلى علاجك الحالي. اسأل طبيبك إذا كان لديك أي استفسارات عن سبب وصف هذا الدواء لك. قد يصف الطبيب ذلك الدواء لسبب آخر. لا يمكن صرف هذا الدواء إلا بوصفة طبية.</p><p>لا يوجد دليل على أن هذا الدواء يسبب الإدمان.</p><p>&nbsp;</p><p><u><strong>ما هي دواعي استعماله</strong></u></p><p>&bull; علاج النوبات الجزئية مع أو بدون التشنجات الثانوية في البالغين والأطفال من سن 6 سنوات من العمر الذين يعانون من الصرع.<br />&bull; علاج النوبات الرمعية لدى البالغين والمراهقين من 12 سنة من العمر ممن يعانون من نوبات الرمعي العضلي.<br />&bull; علاج نوبات الصرع الكبرى لدى البالغين و الاطفال من 12 سنة الذين يعانون من الصرع المعمم الأولي أو مجهول السبب.</p><p>&nbsp;</p><p><u><strong>استخدامه مع الاطفال</strong></u></p><p>لا توجد معلومات كافية لكي يُسمح باستخدام هذا الدواء في علاج الأطفال ممن تقل أعمارهم عن 4 سنوات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>أ- متى يجب عدم استخدام اربك</strong></u></p><p>&bull; إذا مر تاريخ انتهاء الصلاحية (EXP) المطبوع على العبوة.<br />&bull; إذا تمزقت العبوة أو ظهرت عليها علامات العبث أو بدت غير سليمة.<br />&bull; إذا سبقت إصابتك بتفاعل حساسية لعقار اربك أو لأي من المكونات المذكورة في آخر هذه النشرة.</p><p>وتتضمن أعراض تفاعل الحساسية الشعور بضيق التنفس أو أزيز عند التنفس أو صعوبة في التنفس, وتورم بالوجه أو الشفاه أو اللسان أو الحلق أو أجزاء أخرى من الجسم، أو حكة جلدية أو بثور على الجلد.</p><p><strong>إذا ساورك شك أنك أصبت بتفاعل حساسية، فبادر بالاتصال بالطبيب على الفور أو بالذهاب إلى قسم الطوارئ والحوادث في أقرب مستشفى.</strong></p><p>وقد تشتمل أعراض تفاعل الحساسية على بعض أو كل الآتي:</p><p>&bull; السعال أو ضيق النفس أو الأزيز عند التنفس أو صعوبة التنفس<br />&bull; تورم الوجه أو الشفتين أو اللسان أو أجزاء أخرى من الجسم.<br />&bull; الطفح الجلدي أو الحكة الجلدية<br />&bull; الإغماء<br />&bull; الأعراض المشابهة لحمى القش</p><p>&nbsp;</p><p><u><strong>ب- الاحتياطات عند استخدام اربك</strong></u></p><p><strong>قبل بدية تناول هذا الدواء، أخبر طبيبك في الحالات التالية:</strong></p><p>- إذا كنت مصاباً بالحساسية لأي من أي أدويه أخرى، وخاصة أدوية باربتيورات أو أي مضادات صرعية أخرى.<br />- إذا كنت مصاباً بالحساسية لأي من أي مواد أخرى كالأطعمة أو المواد الحافظة أو الأصباغ.<br />- إذا كنت مصاباً أو سبقت إصابتك بأية حالات مرضية وخاصة الآتية:<br />&bull; مشاكل بالكلى (تلف كلوي، قصور كلوي، اختلال وظائف الكلى)<br />&bull; مشاكل بالكبد<br />- إذا كنت قد تلقيت لقاحاً مؤخراً أو تخطط لتلقي أحد اللقاحات.<br />- إذا كنت تخطط لإجراء عملية جراحية.<br />- إذا كنت تتلقى حاليا أو تخطط لتلقي علاجاً للأسنان.</p><p>&nbsp;</p><p><strong>عند استخدام اربك</strong></p><p><strong>أخبر طبيبك على الفور في الحالات التالية:</strong><br />&bull; إذا لاحظت زيادة في النوبات الصرعية (التشنجات)<br />&bull; إذا أصابتك أعراض الاكتئاب أو راودتك أفكار عن إيذاء النفس.</p><p>قم بإبلاغ طبيبك إذا لاحظت أن هذا الدواء لا ينتج عنه تحسن في حالتك. فقد يحتاج طبيبك إلى تغيير علاجك.</p><p>قم بإبلاغ طبيبك إذا لم تتمكن &ndash; لأي سبب &ndash; من تناول هذا الدواء بالكيفية التي وصفها لك الطبيب على وجه الدقة. وإلا فقد يغير طبيبك علاجك بلا داعي.</p><p>أخبر من يقومون بعلاجك من أطباء آخرين أو أطباء الأسنان أو الصيادلة بأنك تتناول هذا الدواء.</p><p><strong>تأكد من الحفاظ على مواعيد زيارة الطبيب حتى يتسنى متابعة تقدم حالتك.</strong></p><p>قد يقوم الطبيب أحياناً بعمل اختبارات للتأكد من عمل الدواء وللوقاية من الأعراض الجانبية. فعليك الذهاب إلى الطبيب بانتظام لإجراء الفحوص الطبية.</p><p>لا تعطي هذا الدواء لأي شخص آخر حتى ولو تشابهت أعراضهم مع أعراضك أو كانوا يعانون من نفس حالتك.</p><p>لا تتناول هذا الدواء لعلاج أي حالة أخرى ما لم ينصحك بذلك الطبيب أو الصيدلي.<br />لا تتوقف عن تناول الدواء أو تقلل الجرعة بدون مراجعة الطبيب.</p><p>&nbsp;</p><p><u><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية</strong></u></p><p>لا يتفاعل اربك مع حبوب منع الحمل. ولكن من الممكن أن يوصف لك اربك مع أدوية أخرى مضادة للصرع من شأنها أن تتداخل مع حبوب منع الحمل والتي قد تقلل من فعالية الحبوب. وقد ينصحك الطبيب باستخدام طريقة إضافية لمنع الحمل إذا تناولت اربك مع أدوية أخرى مضادة للصرع.</p><p>ابلغ طبيبك اذا كنت تخطط لتناول أي أدوية أخرى بما في ذلك الفيتامينات والمكملات الغذائية المتوفرة في الصيدلية أو السوبر ماركت أو محلات الأغذية الصحية.</p><p>&nbsp;</p><p><u><strong>د- تناول اربك مع الطعام والشراب</strong></u></p><p>قد يؤخذ الدواء مع أو بدون الطعام.</p><p>&nbsp;</p><p><u><strong>هـ - الحمل والرضاعة</strong></u></p><p>إذا كنت حاملا في الوقت الراهن أو ترضعين رضاعة طبيعية أو تخططين للحمل أو الإرضاع. فمن الممكن أن يؤثر اربك على جنينك إن قمت بتناوله أثناء فترة الحمل. كما هو شأن معظم الأدوية المضادة للصرع، لا ينصح بتناول اربك أثناء الحمل. ولكن من المهم جدا السيطرة على النوبات الصرعية لديك أثناء فترة الحمل. فإذا كان من الضروري أن تتناولي هذا الدواء، فبإمكان طبيبك المعالج أن يساعدك في اتخاذ القرار بشأن تناوله أو عدم تناوله أثناء فترة الحمل.</p><p>إذا كنت ترضعين طبيعيا أو تخططين لذلك فإن اربك ينفذ إلى حليب الأم.</p><p>&nbsp;</p><p><u><strong>و- تأثيره على القيادة واستخدام الآلات</strong></u></p><p>كن حذرا أثناء القيادة أو تشغيل الآلات إلى أن تعرف تأثير هذا الدواء عليك.</p><p>كغيره من مضادات الصرع، فقد يسبب اربك الخمول أو يؤثر على الوعي لدى بعض الأشخاص. ويكون هذا أكثر حدوثا عند بداية العلاج أو زيادة الجرعة.</p><p>تأكد من معرفتك لكيفية استجابتك لهذا الدواء قبل الإقدام على القيادة السيارة أو تشغيل الآلات أو القيام بأي عمل آخر قد يكون خطراً إذا شعرت بالخمول.</p><p>وينبغي للأطفال عدم ركوب الدراجات أو تسلق الأشجار أو القيام بأي عمل آخر قد يكون خطراً لو شعروا بالخمول أو الميل إلى النعاس.</p><p>الجمع بين تناول هذا الدواء والمشروبات الكحولية قد يزيد من إحساسك بالخمول. قد يقترح طبيبك التوقف عن المشروبات الكحولية خلال فترة علاجك بعقار اربك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u><strong>ماهو المطلوب استخدامه من اربك</strong></u></p><p>اتبع كل توجيهات الطبيب أو الصيدلي بعناية. فقد تختلف تعليماتهم عن المعلومات الموجودة في هذه النشرة.</p><p>بالنسبة للمرضى ممن تبلغ أعمارهم أو تجاوز 12 سنة، تتراوح الجرعة بصفة عامة بين 1000 و3000 ملجم يوميا.</p><p>بالنسبة للأطفال ممن تتراوح أعمارهم من 4 إلى 11 عاماً، تكون الجرعة 20 ملجم/كيلوجرام إلى 60 ملجم/كيلوجرام يوميا.</p><p>لا توجد معلومات تؤيد استخدام هذا الدواء لعلاج المرضى ممن تقل أعمارهم عن 4 سنوات.</p><p>وسوف يخبرك الطبيب أو الصيدلي عن الكمية التي ينبغي أن تتناولها من هذا الدواء. فإن هذا يعتمد على حالتك وعما إذا كنت تتناول أدوية أخرى.</p><p>وقد يوصي الطبيب بأن تبدأ بجرعة منخفضة من اربك &nbsp;وزيادتها ببطء للوصول إلى أقل قدر مطلوب للسيطرة على الصرع / النوبات الصرعية (التشنجات).</p><p>عليك اتباع توجيهات الطبيب بعناية. فقد تختلف عن المعلومات الواردة في هذه النشرة.</p><p>لا تتوقف عن تناول دوائك أو تغير الجرعة بدون مراجعة الطبيب أولا.</p><p>&nbsp;</p><p><u><strong>كيف يستخدم اربك ومتى</strong></u></p><p>قم بابتلاع الأقراص كاملة مع كوب من الماء. يجب تناول هذا الدواء مرتين يوميا، مرة في الصباح وأخرى في المساء، في نفس الموعد تقريبا كل يوم.</p><p>فتناوله في نفس التوقيت كل يوم سيكون له التأثير الأفضل وسيساعدك على تذكر موعد تناوله.</p><p>لا يهم أن تتناوله قبل أو أثناء أو بعد الطعام.</p><p>تستغرق معظم مضادات الصرع وقتا لكي تعمل، لذا لا ينبغي أن يصيبك الإحباط إذا لم تشعر بالتحسن على الفور.</p><p>استمر في تناول الدواء طالما نصحك طبيبك بذلك.</p><p>يساعد هذا الدواء في السيطرة على حالتك ولكنه لا يحقق الشفاء منها. لذا يجب أن تتناول دواءك يوميا حتى ولو شعرت بتحسن.<br />تأكد أن لديك كمية من الدواء تكفي لتغطية الإجازات الأسبوعية والعطلات.</p><p><strong>لا تتوقف عن تناول هذا الدواء أو تغير الجرعة بدون مراجعة الطبيب.</strong></p><p><strong>فالتوقف عن تناول هذا الدواء بشكل مفاجئ قد يسبب آثارا غير مرغوبة أو يجعل حالتك أسوأ. وسوف يقوم طبيبك بتقليل الجرعة ببطء قبل أن تتوقف عن تناوله تماما.</strong></p><p>&nbsp;</p><p><u><strong>أ- الجرعة الزائدة</strong></u></p><p><strong>إذا ساورك شك بأنك أو أي شخص آخر قد تناول جرعة زائدة من هذا الدواء، فبادر على الفور بالاتصال تليفونياً بطبيبك أو بمركز معلومات السموم لطلب المشورة. وكبديل عن هذا، توجه إلى قسم الحوادث والطوارئ في أقرب مستشفى.<br />بادر بذلك وإن لم تظهر أية علامات على عدم الارتياح أو التسمم. فقد تحتاج إلى رعاية طبية عاجلة.</strong></p><p>إذا تناولت جرعة أكثر مما ينبغي من اربك، فقد تشعر بالخمول.</p><p>&nbsp;</p><p><u><strong>ب- الجرعة الفائتة</strong></u></p><p><strong>إذا نسيت تناوله قم بالاتصال بالطبيب إذا فاتتك جرعة أو أكثر.</strong></p><p><strong>لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</strong></p><p>فقد يزيد ذلك فرصة الآثار الجانبية الغير مرغوبة.</p><p>إذا لم تكن متأكدا مما يجب القيام به، فبادر بسؤال طبيبك أو الصيدلي.</p><p>إذا كان لديك صعوبة في تذكر موعد تناول الدواء، فاطلب من الصيدلي بعض النصائح.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قم بإبلاغ الطبيب أو الصيدلي في أقرب وقت ممكن إذا شعرت بسوء خلال فترة تناولك هذا الدواء أو إذا ساورتك أية استفسارات أو مخاوف.</p><p>لا تنزعج من قوائم الآثار الجانبية التالية. فقد لا تتعرض لأي منها. فكل الأدوية قد ينتج عنها آثارا جانبية. والتي قد تكون خطيرة أحيانا ولكنها ليست كذلك في معظم الوقت.</p><p>أبلغ الطبيب أو الصيدلي إذا لاحظت أيا من الأعراض التالية وقد أقلقتك.</p><p>&nbsp;</p><p><strong>الاعراض الاكثر شيوعاً (اكثر من او تساوي 10 % من المرضى)</strong></p><p>&bull; الاصابة العرضية&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; الوهن<br />&bull; صداع الرأس&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; العدوى<br />&bull; النعاس&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p><strong>الاعراض الشائعة (اكثر من او تساوي 1 % و اقل من 10 % من المرضى)</strong></p><p>&bull; ألم في البطن&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ألم في الظهر<br />&bull; ألم في الصدر&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; حرارة<br />&bull; اعراض انفلونزا&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; العداء<br />&bull; فقدان الشهية&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; إسهال<br />&bull; عسر الهضم&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; التهاب في المعدة والامعاء<br />&bull; التهاب اللثة&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; غثيان<br />&bull; مشاكل في الاسنان&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; قيء<br />&bull; كدمات&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; زيادة في الوزن او نقص في الوزن<br />&bull; فقدان الذاكرة&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; القلق<br />&bull; ترنح&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; تشنجات<br />&bull; إكتئاب&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; دوخة<br />&bull; تغيرات في العواطف أو متقلب المزاج<br />&bull; الأرق&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; عصبية<br />&bull; تنمل&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; تفكير شاذ<br />&bull; رعاش&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; دوار<br />&bull; التهاب الشعب الهوائية&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; زيادة في الكحة<br />&bull; التهاب البلعوم&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; التهاب الانف<br />&bull; التهاب الجيوب الانفية&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; حكة<br />&bull; الحول&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; ازدواج في النظر<br />&bull; التهاب الاذن الوسطى&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&bull; التهاب المسالك البولية<br />&bull; الاحساس بالتعب أو نعاس &nbsp;&nbsp; &nbsp;&bull; نزلات البرد</p><p>أخبر طبيبك على الفور إذا لاحظت أي مما يلي. قد تكون هذه الآثار الجانبية الخطيرة. قد تحتاج إلى عناية طبية:<br />&nbsp;&nbsp;</p><ul><li>التغيرات في الحالة المزاجية كالاكتئاب والعصبية والعدوانية والغضب والقلق والاختلاط والهلوسة وسرعة الانفعال.</li><li>التهابات الجهاز التنفسي العلوي</li><li>فقدان الوزن.</li><li>إذا كنت تواجه أي من الأمور التالية، توقف عن أخذ الدواء واتصل بطبيبك فورا أو اذهب إلى قسم الحوادث والطوارئ في أقرب مستشفى. هذه آثار جانبية خطيرة جداً. قد تحتاج إلى عناية طبية عاجلة أو العلاج في المستشفيات.</li><li>التفكير بإيذاء نفسك</li><li>النوبات أكثر تكرارا أو أشد قسوة</li></ul><p>وقد تحدث آثار جانبية أخرى غير المنصوص عليها سالفا لدى بعض المرضى.</p><p>وبعض هذه الآثار الجانبية لا يمكن اكتشافها إلا عندما يقوم طبيبك بعمل اختبارات من وقت لآخر لمتابعة تقدمك.<br />&nbsp;<br />قم بإبلاغ طبيبك إذا لاحظت أي شيء غير ذلك يجعلك تشعر بسوء.</p><p><strong>إذا تعرضت إلى نوبات صرعية (تشنجات) أكثر شدة أو أكثر تكرارا أو راودتك أفكار إيذاء النفس، فبادر بإبلاغ طبيبك على الفور أو بالذهاب إلى قسم الطوارئ والحوادث بأقرب مستشفى.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ &nbsp;بعيدًا عن متناول الأطفال.</p><p>يحفظ هذا الدواء في عبوته الأصلية إلى أن يحين وقت تناوله.</p><p>إذا أخرجت هذا الدواء من عبوته الأصلية، فقد لا يظل بحالة جيدة.</p><p>يحفظ هذا الدواء في مكان بارد جاف حيث لا تزيد درجة الحرارة عن 30 درجة مئوية.<br />لا يحفظ &nbsp;هذا الدواء أو أي دواء آخر في دورة المياه أو قريباً من الحوض. ولا تتركه على عتبة النافذة أو في السيارة. قد تتلف الحرارة والرطوبة بعض الأدوية.</p><p>يحسن حفظ الأدوية في دولاب مغلق على ارتفاع متر ونصف من الأرض على الأقل.</p><p>التخلص من بقايا الدواء: إذا طلب منك الطبيب أو الصيدلي التوقف عن استعمال الدواء أو أن تاريخ صلاحيته انتهى ينبغي أن تسأل الطبيب أو الصيدلي عن طريقة التخلص من الدواء المتبقي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; المادة الفعالة هي ليفيتيراسيتام.</p><p>&bull; باقي المواد هي كوبوفيدون، السليكا اللامائية الغروية، هايبروميلوز، هيدروكسي بروبيل سليلوز، ماكروجول 8000، ثاني أكسيد التايتانيوم، حمض الستريك اللامائي، أكسيد الحديد الأصفر (في الأقراص 500 ملجم و750 ملجم فقط) و أكسيد الحديد الأحمر (في الأقراص 750 ملجم فقط).</p><p>هذا الدواء خالي من الجلوتين واللاكتوز والسكروز والترترازين وصبغات الأزو الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>أقراص 250 ملجم:</strong><br />أقراص بيضاء اللون، بيضاوية الشكل، ثنائية التحدب، مغلفة بطبقة رقيقة، ومحفور على أحد جانبي القرص علامة &quot;LEV&quot; فوق &quot;250&quot; وعلى الجانب الآخر &quot;APO&quot; . في عبوات أشرطة تحتوي على 60 قرص.</p><p><strong>أقراص 500 ملجم:</strong><br />أقراص صفراء اللون، بيضاوية الشكل، ثنائية التحدب، مغلفة بطبقة رقيقة، ومحفور على أحد جانبي القرص علامة &quot;LEV&quot; فوق &quot;500&quot; وعلى الجانب الآخر &quot;APO&quot; . في عبوات أشرطة تحتوي على 60 قرص.</p><p><strong>أقراص 750 ملجم:</strong><br />أقراص برتقالية اللون، بيضاوية الشكل، ثنائية التحدب، مغلفة بطبقة رقيقة، ومحفور<br />فوق &quot; 750 &quot; وعلى الجانب الآخر &quot;LEV&quot; على أحد جانبي القرص علامة<br />في عبوات أشرطة تحتوي على 60 قرص. أيضا في زجاجات تحتوي . &quot;APO&quot;<br />على 60 و 100 و 500 قرص.</p><p><strong>أقراص 1000 ملجم:</strong><br />أقراص بيضاء اللون، بيضاوية الشكل، ثنائية التحدب، مغلفة بطبقة رقيقة، ومحفور<br />فوق &quot; 1000 &quot; وعلى الجانب الآخر &quot;LEV&quot; على أحد جانبي القرص علامة<br />في عبوات أشرطة تحتوي على 60 قرص. أيضا في زجاجات تحتوي .&quot;APO&quot;<br />على 60 و 100 و 500 قرص.</p><p>* قد لا يتم تسويق كل التراكيز والاحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس إنك<br />150 سيجنت درايف<br />تورنتو، أونتاريو M9L 1T9<br />ت: 18002684623، ف: 18006099444<br />www.apotex.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة في: 05/2017

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ARPEK Levetiracetam Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ARPEK 250 mg tablets: White, oval, biconvex, film-coated tablets, engraved “LEV” score “250” on one side, “APO” on the other side.

Blister packs of 60 tablets & Bottles of 60, 100 and 500 tablets.

ARPEK 500 mg tablets: Yellow, oval, biconvex, film-coated tablets, engraved “LEV” score “500” on one side, “APO” on the other side.

Blister packs of 60 tablets & Bottles of 60, 100 and 500 tablets.

ARPEK 750 mg tablets: Orange, oval, biconvex, film-coated tablets, engraved “LEV” score “750” on one side, “APO” on the other side.

Blister packs of 60 tablets & Bottles of 60, 100 and 500 tablets.

ARPEK 1000 mg tablets: White, oval, biconvex, film-coated tablets, engraved “LEV” score “1000” on one side, “APO” on the other side.

Blister packs of 60 tablets & Bottles of 60, 100 and 400 tablets.

ARPEK tablets are intended for oral administration. Each tablet contains 250 mg, 500 mg, 750 mg or 1000 mg levetiracetam, as the active ingredient. In addition, each tablet contains the following inactive ingredients: copovidone, colloidal anhydrous silica, hypromellose, hydroxypropylcellulose, macrogol 8000, titanium dioxide, anhydrous citric acid, iron oxide red (750 mg tablet only) and iron oxide yellow (500 mg & 750 mg tablets only).

* Not all strengths, pack types and/or pack sizes may be available.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ARPEK is film-coated tablet available in dosage strengths of 250 mg, 500 mg, 750 mg & 1000 mg per tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Treatment of partial onset seizures with or without secondary generalization in adults, children from 6 years of age with epilepsy.</li><li>Treatment myoclonic seizures in adults and adolescent from 12 years of age with juvenile Myoclonic.</li><li>Treatment of primary generalized tonic-clonic seizures in adults and children from 12 years of age with idiopathic Generalized Epilepsy.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets must be taken orally, swallowed with liquid. It may be taken with or without food. The daily dose is administered in two equally divided doses.</p><p>&nbsp;</p><p><u>Monotherapy</u></p><p>The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily very two weeks depending upon the clinical response. The maximum dose is 1,500 mg twice daily.</p><p>&nbsp;</p><p><u>Add-On Therapy</u></p><p><u>Adults (&gt; 18 years of age) and Adolescents (aged 12 to 17 years of age) weighing 50 kg or more</u> As adjunctive therapy, the therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerance, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements every two to four weeks.</p><p>&nbsp;</p><p>When satisfactory control of seizures has been attained, monotherapy with levetiracetam may be envisaged by progressively decreasing and withdrawing the concomitant antiepileptic medication.</p><p>&nbsp;</p><p><u>Elderly (65 years and older)</u></p><p>Adjustment of the dose is recommended in the elderly with compromised renal function (see &ldquo;Patients with Renal Impairment&rdquo;, below).</p><p>&nbsp;</p><p><u>Children (aged 4 to 11 years of age) and Adolescents (aged 12 to 17 years of age) weighing less</u> <u>than 50 kg</u></p><p>The initial therapeutic dose is 10 mg/kg twice daily (see Table 1).</p><p>&nbsp;</p><p>Depending on the clinical response and tolerance, the daily dose can be increased up to 60 mg/kg daily (in two 30 mg/kg doses). Dose changes can be made in 10 mg/kg twice daily dose increme nts or decrements every two weeks. The lowest effective dose should be used.</p><p>&nbsp;</p><p>The dosage in children 50 kg or greater is the same as in adults.</p><p>&nbsp;</p><p>The doctor should prescribe the most appropriate pharmaceutical form and strength according to weight and dose.</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> 1: </strong><strong>Recommended</strong><strong> </strong><strong>dosing</strong><strong> </strong><strong>in</strong><strong> </strong><strong>children</strong><strong> </strong><strong>aged</strong><strong> </strong><strong>4 years and older</strong></u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Weight</strong></p></td><td><p><strong>Starting</strong><strong> </strong><strong>Dose:</strong><strong> </strong></p><p><strong>10 mg/kg twice daily</strong></p></td><td><p><strong>Maximum</strong><strong> </strong><strong>Dose:</strong><strong> </strong></p><p><strong>30</strong><strong> </strong><strong>mg/kg</strong><strong> </strong><strong>twice</strong><strong> </strong><strong>daily</strong></p></td></tr><tr><td><p>15 kg (1)</p></td><td><p>150 mg twice daily</p></td><td><p>450 mg twice daily</p></td></tr><tr><td><p>20 kg (2)</p></td><td><p>200 mg twice daily</p></td><td><p>600 mg twice daily</p></td></tr><tr><td><p>25 kg</p></td><td><p>250 mg twice daily</p></td><td><p>750 mg twice daily</p></td></tr><tr><td><p>From 50 kg (2)</p></td><td><p>500 mg twice daily</p></td><td><p>1500 mg twice daily</p></td></tr></tbody></table><p>(1)&nbsp;Children 20 kg or less should preferably start the treatment with a Levetiracetam 100 mg/mL oral solution.</p><p>(2)&nbsp;Dosage in children and adolescents 50 kg or more is the same as in adults.</p><p>&nbsp;</p><p><u>Infants &amp; Children less than 4 Years of Age</u></p><p>There are insufficient data to recommend the use of levetiracetam in children under 4 years of age.</p><p>&nbsp;</p><p><u>Patients with Renal Impairment</u></p><p>The levetiracetam daily dose must be individualised according to renal function. For adult patients, see Table 2 and adjust the dose as indicated.</p><p>&nbsp;</p><p>To use this dosing table an estimate of the patient&#39;s creatinine clearance (ClCr) in mL/minute is needed. The ClCr in mL/minute may be estimated from serum creatinine (&micro;mol/L) determination using the following formula.</p><p>&nbsp;</p><p>CLcr (mL/min/1.73m2) =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>CLcr (mL/min) x 1.73 &nbsp;&nbsp;&nbsp;&nbsp; </u></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;BSA subject (m2)</p><p>&nbsp;</p><p>&nbsp;</p><p>CLcr&nbsp;=&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u> [140 &ndash; age (years)] x weight (kg)&nbsp;&nbsp;(x 0.85 for women) </u></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.8136 x serum creatinine (&micro;mol/L)</p><p>&nbsp;</p><p>&nbsp;</p><p>The CICr is adjusted for body surface area (BSA) as follows:</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> </strong><strong>2:</strong><strong> </strong><strong>Adult</strong><strong> </strong><strong>dosage</strong><strong> </strong><strong>schedule</strong><strong> </strong><strong>based</strong><strong> </strong><strong>on</strong><strong> </strong><strong>renal</strong><strong> </strong><strong>function</strong></u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>Group</strong></p></td><td><p><strong>Creatinine</strong><strong> </strong><strong>Clearance</strong><strong> </strong></p><p><strong>(mL/min/1.73m</strong><strong>2</strong><strong>)</strong></p></td><td><p><strong>Dosage</strong><strong> </strong><strong>(mg)</strong></p></td><td><p><strong>Frequency</strong><strong> </strong><strong>(daily</strong></p></td></tr><tr><td><p>Normal</p></td><td><p>&gt; 80</p></td><td><p>500 to 1500</p></td><td><p>Twice</p></td></tr><tr><td><p>Mild</p></td><td><p>50-79</p></td><td><p>500 to 1500</p></td><td><p>Twice</p></td></tr><tr><td><p>Moderate</p></td><td><p>30-49</p></td><td><p>250 to 750</p></td><td><p>Twice</p></td></tr><tr><td><p>Severe</p></td><td><p>&lt; 30</p></td><td><p>250 to 500</p></td><td><p>Twice</p></td></tr><tr><td><p>End-stage renal disease patients&nbsp;</p><p>undergoing dialysis (1)</p></td><td><p>--</p></td><td><p>500 to 1000</p></td><td><p>Once (2)</p></td></tr></tbody></table><p>(1)&nbsp;A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.</p><p>(2)&nbsp;Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>&nbsp;</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.</p><p>&nbsp;</p><p><u>Patients with Hepatic Impairment</u></p><p>No dose adjustment is needed in patients with mild and moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore, a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 70 mL/minute.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to levetiracetam or other pyrrolidone derivatives.
•	Hypersensitivity to any other excipients in Levetiracetam tablets (see PHARMACEUTICAL PARTICULARS).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In accordance with current clinical practice, if levetiracetam has to be discontinued it is recommended to withdraw it gradually.</p><p>&nbsp;</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. There is no need, therefore, for plasma level monitoring of levetiracetam.</p><p>&nbsp;</p><p>To date, there are no data to support the use of levetiracetam in patients less than 4 years of age. No data on the interaction of levetiracetam with alcohol are available.</p><p>&nbsp;</p><p><u>Suicidal Behaviour &amp; Ideation</u></p><p>Antiepileptic drugs, including levetiracetam, increase the risk of suicidal thoughts or behaviour in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behaviour and/or any unusual changes in mood or behaviour.</p><p>&nbsp;</p><p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomised to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behaviour compared to patients randomised to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behaviour or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behaviour for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.</p><p>&nbsp;</p><p>The increased risk of suicidal thoughts or behaviour with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behaviour beyond 24 weeks could not be assessed.</p><p>&nbsp;</p><p>The risk of suicidal thoughts or behaviour was generally consistent among drugs in the data analysed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analysed. Table 3 shows absolute and relative risk by indication for all evaluated AEDs.</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> </strong><strong>3: </strong><strong>Risk</strong><strong> </strong><strong>by indication for antiepileptic drugs in the pooled analysis</strong></u></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Placebo<strong> </strong>Patients<strong> </strong>with Events / 1000 Patients</strong></p></td><td><p><strong>Drug<strong> </strong>Patients with Events / 1000 Patients</strong></p></td><td><p><strong>Relative</strong><strong> </strong><strong>Risk:</strong><strong> </strong><strong>Incidence</strong><strong> </strong><strong>of Events in Drug Patients / Incidence in Placebo Patients</strong></p></td><td><p><strong>&nbsp;Risk<strong> </strong>Difference:</strong><strong> </strong><strong>Additional Drug Patients with Events per 1000 Patients</strong></p></td></tr><tr><td><p>Epilepsy</p></td><td><p>1.0</p></td><td><p>3.4</p></td><td><p>3.5</p></td><td><p>2.4</p></td></tr><tr><td><p>Psychiatric</p></td><td><p>5.7</p></td><td><p>8.5</p></td><td><p>1.5</p></td><td><p>2.9</p></td></tr><tr><td><p>Other</p></td><td><p>1.0</p></td><td><p>1.8</p></td><td><p>1.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Total</p></td><td><p>2.4</p></td><td><p>4.3</p></td><td><p>1.8</p></td><td><p>1.9</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The relative risk for suicidal thoughts or behaviour was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.</p><p>&nbsp;</p><p>Anyone considering prescribing levetiracetam or any other AED must balance this risk with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behaviour. Should suicidal thoughts and behaviour emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to illness being treated.</p><p>&nbsp;</p><p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behaviour and should be advised of the need to be alert for the emergence of worsening of the signs and symptoms of depression, any unusual changes in mood or behaviour, or the emergence of suicidal thoughts, behaviour, or thoughts about self-harm. Behaviours of concern should be reported immediately to the treating doctor.</p><p>&nbsp;</p><p><strong>Impaired Renal Function</strong></p><p>The administration of levetiracetam to patients with renal impairment may require dose adaptation. Monitoring of renal function in patients with severe hepatic impairment is recommended before dose selection (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><strong>Impaired Hepatic Function</strong></p><p>See &ldquo;Impaired Renal Function&rdquo;.</p><p>&nbsp;</p><p><strong>Carcinogenesis and Mutagenesis</strong></p><p><u>Carcinogeniticy</u></p><p>There was no evidence of carcinogenicity following administration of levetiracetam in the diet to rats or orally to mice for 104 weeks, associated with respective systemic exposures (plasma AUC) up to fourfold and eightfold that in humans at the maximal recommended clinical dose of 3,000 mg/day.</p><p>&nbsp;</p><p><u>Genotoxicity</u></p><p>Levetiracetam was negative in gene mutation assays (bacterial, Chinese hamster ovary/ HGPRT locus) and in assays for chromosomal damage <em>in vitro </em>and <em>in vivo </em>(Chinese hamster ovary cells, mouse micronucleus assay). The hydrolysis product and major human metabolite (ucb L057) was not mutagenic in bacterial reverse mutation assays or the in vitro mouse lymphoma assay.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro, levetiracetam and its major metabolite (ucb L057) have been shown not to inhibit the major human liver cytochrome P450 isoforms, glucuronyl transferase, (valproic acid) and epoxide hydroxylase activities. In human hepatocytes in culture, levetiracetam did not cause enzyme induction.</p><p>&nbsp;</p><p>Probenecid has been shown to inhibit the renal clearance of the major metabolite (ucb L057) but not levetiracetam. Nevertheless, the concentration of ucb L057 remains low. It is expected that other drugs excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted drugs (e.g. NSAIDs, sulphonamides, and methotrexate) is unknown.</p><p>&nbsp;</p><p>Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbitone, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.</p><p>&nbsp;</p><p>Consistent with formal pharmacokinetic studies in adults, there has been no clear evidence of clinically significant drug interactions in paediatric patients receiving up to 60 mg/kg/day.</p><p>&nbsp;</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine, valproate, topiramate and lamotrigine. However, data suggested that enzyme inducing antiepileptic medicinal products increase levetiracetam clearance by 22%. Dosage adjustment is not required.</p><p>&nbsp;</p><p>Pharmacokinetic studies demonstrated a lack of interaction with digoxin, oral contraceptives (ethinyloestradiol and levonorgestrel) and warfarin. Endocrine parameters (luteinising hormone (LH) and progesterone) and prothrombin times were not modified.</p><p>&nbsp;</p><p>No data on the influence of antacids on the absorption of levetiracetam are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on Fertility</strong></p><p>There are no human data on the effects of levetiracetam on male or female fertility. No adverse effects on male or female fertility or reproductive performance were observed in rats at oral doses of levetiracetam up to 1,800 mg/kg/day (corresponding to approximately six times the maximal recommended clinical dose on a mg/m2&nbsp;basis) administered for at least two weeks prior to, and throughout, mating.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category C)</strong></p><p>In rats and rabbits, levetiracetam and/or its metabolites cross the placenta and the foetal levels approximate maternal plasma levels. In these species, levetiracetam produced evidence of developmental toxicity at doses similar to or greater than human therapeutic doses.</p><p>&nbsp;</p><p>Oral administration to female rats from two weeks prior to mating and throughout pregnancy and lactation was associated with increased incidences of minor foetal skeletal abnormalities and retarded offspring growth prenatally and/or postnatally at doses greater than or equal to 350 mg/kg/day (approximately equivalent to the maximal recommended clinical dose of 3,000 mg/day on a mg/m2&nbsp;basis) and with increased pup mortality and offspring behavioural alterations at a dose of 1,800 mg/kg/day (six times the maximal human dose on a mg/m2&nbsp;basis). The developmental no effect dose was 70 mg/kg/day (equivalent to 0.2 times the maximal human dose on a mg/m2&nbsp;basis). There was no overt maternal toxicity at the doses used in this study.</p><p>Oral administration to pregnant rabbits during the period of organogenesis resulted in increased embryofoetal mortality and increased incidences of minor foetal skeletal abnormalities at doses greater than or equal to 600 mg/kg/day (about four times the maximal human dose on a mg/m2&nbsp;basis) and in decreased foetal weights and increased incidences of minor foetal skeletal anomalies at a dose of 1,800 mg/kg/day (12 times the maximal human dose on a mg/m2&nbsp;basis). The developmental no effect dose was 200 mg/kg/day (1.3 times the maximal human dose on a mg/m2&nbsp;basis). Maternal toxicity was also observed at 1,800 mg/kg/day.</p><p>Oral administration to pregnant rats during the period of organogenesis resulted in reduced foetal weight and increased incidence of embryofoetal mortality and increased incidence of foetal skeletal variations at a dose of 3,600 mg/kg/day (12 times the maximal human dose on a mg/m2&nbsp;basis). The developmental no effect dose was 1,200 mg/kg/day (four times the maximal human dose on a mg/m2&nbsp;basis). There was no overt maternal toxicity.</p><p>Oral administration to rats during the late gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1,800 mg/kg/day (six times the maximal human dose on a mg/m2&nbsp;basis). Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses of up to 1,800 mg/kg/day (30 times the maximal human dose).</p><p>The risk of having an abnormal child as a result of antiepileptic medication is far outweighed by the dangers to the mother and foetus of uncontrolled epilepsy.</p><p>It is recommended that:</p><ul><li>Women on AEDs receive pre-pregnancy counselling with regard to the risk of foetal abnormalities;</li><li>AEDs should be continued during pregnancy and monotherapy should be used if possible at the lowest effective dose as risk of abnormality is greater in women taking combined medication;</li><li>Folic acid supplementation (5 mg) should be commenced four weeks prior to and continue for 12 weeks after conception;</li><li>Specialist prenatal diagnosis including detailed mid-trimester ultrasound should be offered.</li></ul><p>To date, insufficient clinical data on exposed pregnancies are available. Levetiracetam should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. As with other antiepileptic drugs, physiological changes during pregnancy may affect levetiracetam concentration. There have been reports of decreased levetiracetam concentrations during pregnancy.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>Levetiracetam and/or its metabolites are excreted in milk in lactating rats; peak milk concentrations occurred three hours after oral administration (milk:plasma ratio 0.9). Levetiracetam is excreted in breast milk. Because of the potential for serious adverse reactions in breastfeeding infants from levetiracetam, a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>Due to possible different individual sensitivity, some patients might experience, at the beginning of treatment or following a dosage increase, somnolence or other central nervous system (CNS) related symptoms. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The prescriber should be aware that the following data were obtained from studies where levetiracetam was added to concomitant antiepileptic therapy. Therefore, it was not possible in all cases to determine which agent(s), if any, was associated with the adverse events. It is also difficult to predict the frequency of adverse events in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies.</p><p>&nbsp;</p><p><strong>Adult Patients</strong></p><p>Levetiracetam has been administered to more than 3,000 subjects and patients. Of these, 780 patients were treated for more than six months, 592 for more than one year, 366 for more than two years and 185 for more than three years.</p><p>&nbsp;</p><p>1,023 adult patients with epilepsy participated in controlled clinical trials (672 patients were treated with levetiracetam and 351 patients with placebo).</p><p>&nbsp;</p><p>From placebo controlled studies conducted in adults, 46.4 and 42.2% of patients experienced drug related, treatment emergent adverse events in the levetiracetam group and placebo group, respectively. 2.4 and 2.0% of patients experienced serious drug related, treatment emergent adverse events in the levetiracetam group and placebo group, respectively.</p><p>&nbsp;</p><p>During monotherapy treatment with levetiracetam, 79.6% of subjects experienced at least one adverse event and 49.8% experienced at least one drug related undesirable effect. The most frequently reported adverse effects were fatigue and somnolence.</p><p>&nbsp;</p><p><strong>Very Common Adverse Events (greater than or equal to 10%)</strong></p><p>The very common adverse events (greater than or equal to 10%) were somnolence, asthenia, infection, headache and accidental injury. Of these, somnolence, asthenia and infection appeared to occur more frequently in levetiracetam treated patients than in placebo treated patients, whereas accidental injury was more common in the placebo group and headache was similarly reported in the two groups (see Table 4).</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> </strong><strong>4:</strong><strong> </strong><strong>Incidence</strong><strong> </strong><strong>(%)</strong><strong> </strong><strong>of</strong><strong> </strong><strong>very</strong><strong> </strong><strong>common</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>emergent</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>events</strong><strong> </strong><strong>in adult placebo controlled studies, by body system</strong></u></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>Body</strong><strong> </strong><strong>System</strong><strong> </strong><strong>/ Adverse Even</strong></p></td><td><p><strong>Levetiracetam</strong><strong> </strong><strong>group</strong><strong> </strong></p><p><strong>(n</strong><strong> </strong><strong>= 672)</strong></p><p><strong>%</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>group</strong><strong> </strong></p><p><strong>(n</strong><strong> </strong><strong>= 351)</strong></p><p><strong>%</strong></p></td></tr><tr><td colspan="3"><p><strong>Body</strong><strong> </strong><strong>as</strong><strong> </strong><strong>a Whole</strong></p></td></tr><tr><td><p>Accidental Injury</p></td><td><p>10.3</p></td><td><p>16.5</p></td></tr><tr><td><p>Asthenia</p></td><td><p>14.1</p></td><td><p>9.7</p></td></tr><tr><td><p>Headache</p></td><td><p>13.1</p></td><td><p>13.7</p></td></tr><tr><td><p>Infection</p></td><td><p>13.2</p></td><td><p>7.4</p></td></tr><tr><td colspan="3"><p><strong>Nervous</strong><strong> </strong><strong>System</strong></p></td></tr><tr><td><p>Somnolence</p></td><td><p>14.9</p></td><td><p>9.7</p></td></tr></tbody></table><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>In the pooled safety analysis, there was no clear dose response relationship but incidence and severity of CNS related undesirable effects decreased over time.</p><p>&nbsp;</p><p>More than 93% of events categorised under the COSTART preferred term &#39;infection&#39; are symptoms of community acquired infections (common cold and upper respiratory tract infections). There was no increase in incidence of other infections (e.g. lower respiratory tract infections, urinary tract infections). Minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 x 106/mm2), mean haemoglobin (0.9 g/L) and mean haematocrit (0.38%) were seen in levetiracetam treated patients in controlled trials. A total of 3.2% of treated and 1.8% of placebo patients had at least one possibly significant (less than or equal to 2.8 x 109/L) decreased WBC, and 2.4% for treated and 1.4% of placebo patients had at least one possible significant (less than or equal to 1.0 x 109/L) decreased neutrophil count. Of the treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.</p><p>&nbsp;</p><p><strong>Common Adverse Events (greater than or equal to 1% and &lt; 10%)</strong></p><p>See Table 5.</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> </strong><strong>5:</strong><strong> </strong><strong>Incidence</strong><strong> </strong><strong>(%)</strong><strong> </strong><strong>of</strong><strong> </strong><strong>common</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>emergent</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>events </strong><strong>in</strong><strong> </strong><strong>adult</strong><strong> </strong><strong>placebo</strong><strong> </strong><strong>controlled</strong><strong> </strong><strong>studies,</strong><strong> </strong><strong>by body system</strong></u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body</strong><strong> </strong><strong>System</strong><strong> </strong><strong>/ Adverse Event</strong></p></td><td><p><strong>Levetiracetam</strong><strong> </strong><strong>group</strong></p><p><strong>(n</strong><strong> </strong><strong>= 672)</strong></p><p><strong>%</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>group</strong><strong> </strong></p><p><strong>(n</strong><strong> </strong><strong>= 351)</strong></p><p><strong>%</strong></p></td></tr><tr><td><p><strong>Body</strong><strong> </strong><strong>as</strong><strong> </strong><strong>a Whole</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Abdominal Pain</p></td><td><p>3.7</p></td><td><p>5.1</p></td></tr><tr><td><p>Back Pain</p></td><td><p>4.0</p></td><td><p>4.6</p></td></tr><tr><td><p>Chest Pain</p></td><td><p>1.3</p></td><td><p>1.1</p></td></tr><tr><td><p>Drug Level Increased</p></td><td><p>1.3</p></td><td><p>0.9</p></td></tr><tr><td><p>Fever</p></td><td><p>1.3</p></td><td><p>1.7</p></td></tr><tr><td><p>Flu Syndrome</p></td><td><p>4.2</p></td><td><p>6.0</p></td></tr><tr><td><p>Hostility</p></td><td><p>2.1</p></td><td><p>0.6</p></td></tr><tr><td><p>Pain</p></td><td><p>6.5</p></td><td><p>6.6</p></td></tr><tr><td><p><strong>Digestive</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anorexia</p></td><td><p>2.4</p></td><td><p>2.0</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>4.2</p></td><td><p>5.1</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>2.8</p></td><td><p>3.4</p></td></tr><tr><td><p>Gastroententeritis</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Gingivitis</p></td><td><p>1.2</p></td><td><p>0.6</p></td></tr><tr><td><p>Nausea</p></td><td><p>4.2</p></td><td><p>4.6</p></td></tr><tr><td><p>Tooth Disorder</p></td><td><p>1.5</p></td><td><p>0.6</p></td></tr><tr><td><p>Vomiting</p></td><td><p>2.2</p></td><td><p>2.0</p></td></tr><tr><td><p><strong>Haemic</strong><strong> </strong><strong>&amp; Lymph System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ecchymosis</p></td><td><p>1.5</p></td><td><p>1.1</p></td></tr><tr><td><p><strong>Metabolic</strong><strong> </strong><strong>/ Nutritional Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Weight Gain</p></td><td><p>1.2</p></td><td><p>1.1</p></td></tr><tr><td><p><strong>Nervous</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Amnesia</p></td><td><p>1.6</p></td><td><p>0.3</p></td></tr><tr><td><p>Anxiety</p></td><td><p>1.6</p></td><td><p>1.1</p></td></tr><tr><td><p>Ataxia</p></td><td><p>2.5</p></td><td><p>1.4</p></td></tr><tr><td><p>Convulsion</p></td><td><p>6.0</p></td><td><p>6.8</p></td></tr><tr><td><p>Depression</p></td><td><p>4.0</p></td><td><p>2.3</p></td></tr><tr><td><p>Dizziness</p></td><td><p>9.2</p></td><td><p>4.3</p></td></tr><tr><td><p>Emotional Lability</p></td><td><p>1.6</p></td><td><p>0.3</p></td></tr><tr><td><p>Insomnia</p></td><td><p>3.0</p></td><td><p>2.8</p></td></tr><tr><td><p>Nervousness</p></td><td><p>3.9</p></td><td><p>1.7</p></td></tr><tr><td><p>Paraesthesia</p></td><td><p>1.9</p></td><td><p>1.7</p></td></tr><tr><td><p>Thinking Abnormal</p></td><td><p>1.5</p></td><td><p>1.4</p></td></tr><tr><td><p>Tremor</p></td><td><p>1.5</p></td><td><p>1.7</p></td></tr><tr><td><p>Vertigo</p></td><td><p>2.5</p></td><td><p>1.4</p></td></tr><tr><td><p><strong>Respiratory</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Bronchitis</p></td><td><p>1.3</p></td><td><p>1.4</p></td></tr><tr><td><p>Cough Increased</p></td><td><p>2.1</p></td><td><p>1.7</p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>5.7</p></td><td><p>3.7</p></td></tr><tr><td><p>Rhinitis</p></td><td><p>4.3</p></td><td><p>2.6</p></td></tr><tr><td><p>Sinusitis</p></td><td><p>2.1</p></td><td><p>0.9</p></td></tr><tr><td><p><strong>Skin</strong><strong> </strong><strong>&amp; Appendages</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash</p></td><td><p>2.8</p></td><td><p>4.0</p></td></tr><tr><td><p><strong>Special </strong><strong>Senses</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Amblyopia</p></td><td><p>1.2</p></td><td><p>1.4</p></td></tr><tr><td><p>Diplopia</p></td><td><p>2.4</p></td><td><p>1.7</p></td></tr><tr><td><p>Otitis Media</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p><strong>Urogenital</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Urinary Tract Infection</p></td><td><p>1.9</p></td><td><p>3.4</p></td></tr></tbody></table><p>The incidence of serious adverse events in placebo controlled studies was 9.9% in the levetiracetam group versus 8.9% in the placebo group. Many of the serious adverse events are typical for a population of patients with epilepsy.</p><p>The serious adverse events which occurred in more than 1% of patients were convulsion (1.8% in levetiracetam group versus 1.4% in placebo group) and accidental injury (1.6% in both levetiracetam and placebo group).</p><p>&nbsp;</p><p><strong>Paediatric Patients</strong></p><p>A study conducted in paediatric patients (4 to 16 years of age) showed that 55.4 and 40.2% of the paediatric patients experienced undesirable effects in the levetiracetam and placebo groups, respectively, and that 0.0 and 1.0% of the paediatric patients experienced serious undesirable effects in the levetiracetam and placebo groups, respectively.</p><p>&nbsp;</p><p>In the paediatric clinical study, 16.8% of patients receiving levetiracetam and 20.6% receiving placebo either discontinued or had a dose reduction as a result of an adverse event. The most commonly reported undesirable effects in the paediatric population were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache. Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults, except for behavioural and psychiatric undesirable effects which were more common in children than in adults (38.6 versus 18.6%). However, the relative risk was similar in children as compared to adults as there was also a higher incidence of behavioural psychiatric adverse events in the placebo group in children as compared to adults (27.8 versus 10.5%) (see Table 6).</p><p>&nbsp;</p><p><u><strong>Table</strong><strong> </strong><strong>6:</strong><strong> </strong><strong>Incidence</strong><strong> </strong><strong>(%)</strong><strong> </strong><strong>of</strong><strong> </strong><strong>treatment</strong><strong> </strong><strong>emergent</strong><strong> </strong><strong>adverse</strong><strong> </strong><strong>events</strong><strong> </strong><strong>in a placebo controlled, add-on study in paediatric patients aged 4-16 years, by body system (adverse events occurred in at least 2% of Levetiracetam treated patients and occurred more frequently than placebo treated patients)</strong></u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body</strong><strong> </strong><strong>System</strong><strong> </strong><strong>/ Adverse Event</strong></p></td><td><p><strong>Levetiracetam</strong><strong> </strong><strong>group</strong><strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>(n</strong><strong> </strong><strong>= 101)</strong></p><p><strong>&nbsp;</strong></p><p><strong>%</strong></p></td><td><p><strong>Placebo</strong><strong> </strong><strong>group</strong><strong> </strong></p><p><strong>(n</strong><strong> </strong><strong>= 97)</strong></p><p><strong>%</strong></p></td></tr><tr><td><p><strong>Body</strong><strong> </strong><strong>as</strong><strong> </strong><strong>a Whole</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Accidental Injury</p></td><td><p>17</p></td><td><p>10</p></td></tr><tr><td><p>Asthenia</p></td><td><p>9</p></td><td><p>3</p></td></tr><tr><td><p>Pain</p></td><td><p>6</p></td><td><p>3</p></td></tr><tr><td><p>Flu Syndrome</p></td><td><p>3</p></td><td><p>2</p></td></tr><tr><td><p>Face Oedema</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Neck Pain</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Viral Infection</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Digestive</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vomiting</p></td><td><p>15</p></td><td><p>13</p></td></tr><tr><td><p>Anorexia</p></td><td><p>13</p></td><td><p>8</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>8</p></td><td><p>7</p></td></tr><tr><td><p>Gastroententeritis</p></td><td><p>4</p></td><td><p>2</p></td></tr><tr><td><p>Constipation</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p><strong>Haemic</strong><strong> </strong><strong>&amp; Lymph System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ecchymosis</p></td><td><p>4</p></td><td><p>1</p></td></tr><tr><td><p><strong>Metabolic</strong><strong> </strong><strong>/ Nutritional Disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dehydration</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Nervous</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Somnolence</p></td><td><p>23</p></td><td><p>11</p></td></tr><tr><td><p>Hostility</p></td><td><p>12</p></td><td><p>6</p></td></tr><tr><td><p>Nervousness</p></td><td><p>10</p></td><td><p>2</p></td></tr><tr><td><p>Personality Disorder</p></td><td><p>8</p></td><td><p>7</p></td></tr><tr><td><p>Dizziness</p></td><td><p>7</p></td><td><p>2</p></td></tr><tr><td><p>Emotional Lability</p></td><td><p>6</p></td><td><p>4</p></td></tr><tr><td><p>Agitation</p></td><td><p>6</p></td><td><p>1</p></td></tr><tr><td><p>Depression</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p>Vertigo</p></td><td><p>3</p></td><td><p>1</p></td></tr><tr><td><p>Reflexes Increased</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p>Confusion</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Respiratory</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rhinitis</p></td><td><p>13</p></td><td><p>8</p></td></tr><tr><td><p>Cough Increased</p></td><td><p>11</p></td><td><p>7</p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>10</p></td><td><p>8</p></td></tr><tr><td><p>Asthma</p></td><td><p>2</p></td><td><p>1</p></td></tr><tr><td><p><strong>Skin</strong><strong> </strong><strong>&amp; Appendages</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pruritus</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p>Skin Discolouration</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p>Vesiculobullous Rash</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Special </strong><strong>Senses</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Conjunctivitis</p></td><td><p>3</p></td><td><p>2</p></td></tr><tr><td><p>Amblyopia</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p>Ear Pain</p></td><td><p>2</p></td><td><p>0</p></td></tr><tr><td><p><strong>Urogenital</strong><strong> </strong><strong>System</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Albuminuria</p></td><td><p>4</p></td><td><p>0</p></td></tr><tr><td><p>Urine Abnormality</p></td><td><p>2</p></td><td><p>1</p></td></tr></tbody></table><p>&nbsp;</p><p>Other events occurring in 2% or more of paediatric patients treated with levetiracetam but as or more frequent in the placebo group were the following: abdominal pain, allergic reaction, ataxia, convulsion, epistaxis, fever, headache, hyperkinesia, infection, insomnia, nausea, otitis media, rash, sinusitis, status epilepticus (not otherwise specified), thinking abnormal, tremor and urinary incontinence.</p><p>&nbsp;</p><p><strong>Other Controlled Clinical Trials</strong></p><p>The following adverse effects, listed by body system, have been observed in additional controlled clinical trials.</p><p>&nbsp;</p><p><u>General Disorders</u></p><p>Very Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue.</p><p><u>Respiratory System</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis.</p><p><u>Nervous System</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Balance disorder, disturbance in attention, memory impairment.</p><p><u>Skin &amp; Subcutaneous Tissue Disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eczema, pruritus.</p><p><u>Eye Disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision blurred.</p><p>&nbsp;</p><p><u>Blood &amp; Lymphatic System Disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia.</p><p><u>Musculoskeletal &amp; Connective Tissue Disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myalgia.</p><p><u>Psychiatric Disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, mood swings, personality disorder.</p><p>&nbsp;</p><p><strong><u>Post-Marketing Experience</u></strong></p><p>In post-marketing experience, nervous system and psychiatric disorders have been most frequently reported.</p><p>In addition to the adverse reactions reported during clinical studies and listed above, the following adverse reactions have been reported in post-marketing experience. Data are insufficient to support an estimate of their incidence in the population to be treated.</p><p>&nbsp;</p><p><u>Blood &amp; Lymphatic System Disorders</u></p><p>Pancytopenia with bone marrow suppression identified in some of these cases, leucopenia and neutropenia.</p><p>&nbsp;</p><p><u>Psychiatric Disorders</u></p><p>Abnormal behaviour, aggression, anger, confusion, hallucination, psychotic disorder, suicide, suicide attempt and suicidal ideation.</p><p>&nbsp;</p><p><u>Skin &amp; Subcutaneous Tissue Disorders</u></p><p>Alopecia; in several cases, recovery was observed when levetiracetam was discontinued.</p><p><u>Liver &amp; Biliary System Disorders</u></p><p>Hepatitis, hepatic failure and abnormal liver function test.</p><p><u>Metabolic &amp; Nutritional Disorders</u></p><p>Weight loss, pancreatitis.</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>The highest known dose of levetiracetam received in the clinical development program was 6,000 mg/day. Other than drowsiness, there were no adverse events in the few known cases of overdose in clinical trials.</p><p>Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses in post-marketing use.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>There is no specific antidote for levetiracetam. Treatment for an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the major metabolite (ucb L057).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamics in Animals</u></p><p>Levetiracetam is not active in the classical screening models for anticonvulsants, however it induces potent protection in a broad range of animal models of partial and primary generalised seizures, with an unusually high safety margin between therapeutic doses and doses inducing adverse effects.</p><p>Levetiracetam also displays potential antiepileptogenic properties by dose dependently inhibiting the development of kindling, even after discontinuation of the active substance.</p><p>Withdrawal from chronic treatment did not decrease the seizure threshold. Anxiolytic action and an absence of undesirable effects on cognitive function have also been observed.</p><p>The major metabolite, ucb L057, is inactive in seizure models.</p><p>&nbsp;</p><p><u>Pharmacodynamics in Humans</u></p><p>Both partial and generalised epilepsy models (epileptiform discharge/photoparoxysmal response) confirmed the broad spectrum preclinical pharmacological profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear and time independent with low intrasubject and intersubject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p>&nbsp;</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of levetiracetam.</p><p>&nbsp;</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/ plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after four hours postdose for oral solution formulation).</p><p>&nbsp;</p><p>A single dose of levetiracetam 1,500 mg diluted in 100 mL of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to levetiracetam 1,500 mg oral intake, given as three 500 mg tablets.</p><p>&nbsp;</p><p>The intravenous administration of doses up to 4,000 mg diluted in sodium chloride 0.9% 100 mL infused over 15 minutes and doses up to 2,500 mg diluted in sodium chloride 0.9% 100 mL infused over five minutes was evaluated.</p><p>&nbsp;</p><p>The pharmacokinetic and safety profiles did not identify any safety concerns.</p><p>&nbsp;</p><p><u>Adults and Adolescents</u></p><p><em>Absorption:&nbsp;</em></p><p>Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100%. Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady state is achieved after two days of a twice daily administration schedule. Peak concentrations (Cmax) are typically 31 and</p><p>43 &micro;g/mL following a single 1,000 mg dose and repeated 1,000 mg twice daily (bid) dose, respectively. The extent of absorption is dose independent and is not altered by food but the rate of absorption is slightly reduced.</p><p>&nbsp;</p><p><em>Distribution:</em></p><p>No tissue distribution data are available in humans. Neither levetiracetam nor its major metabolite</p><p>(ucb L057) are significantly bound to plasma proteins (&lt; 10%). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 L/kg, a value close to the volume of distribution of intracellular and extracellular water.</p><p>&nbsp;</p><p><em>Metabolism:</em></p><p>The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of this metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including whole blood but not plasma. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose).</p><p>Other unidentified components accounted for only 0.6% of the dose.</p><p>No enantiomeric interconversion was evidenced <em>in vivo </em>for either levetiracetam or its major metabolite ucb L057. <em>In vitro</em>, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the <em>in vitro </em>glucuronidation of valproic acid.</p><p>In human hepatocytes <em>in vitro</em>, levetiracetam had no effect on CYP1A/2 or UGT isoform activities (including ethinyloestradiol conjugation). Levetiracetam caused mild induction of CYP2B6 and CYP3A4, but only at high concentrations not considered to be clinically relevant. Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely.</p><p>&nbsp;</p><p><em>Excretion:&nbsp;</em></p><p>The plasma half-life in adults was 7.2 +/- 1.1 hours and did not vary either with dose, route of administration or repeated administration. The total body clearance was a mean of 0.96 +/- 0.14 mL/minute/kg.</p><p>&nbsp;</p><p>The major route of excretion was via urine, accounting for a mean 95% of the dose, with approximately 93% of the dose excreted within 48 hours. Excretion via faeces accounted for only 0.3% of the dose. The cumulative urinary excretion of levetiracetam and its major metabolite (ucb L057) accounted for 66 and 24% of the dose, respectively, during the first 48 hours.</p><p>&nbsp;</p><p>The renal clearance of levetiracetam is 0.6 mL/minute/kg, indicating that it is excreted by glomerular filtration with subsequent tubular reabsorption. The renal clearance of the major metabolite, ucb L057, is 4.2 mL/minute/kg indicating active tubular secretion in addition to glomerular filtration.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>In elderly patients, the half-life is increased by about 40% (ten to eleven hours) and is attributed to the decrease in renal function in this population (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p><u>Children (4 to 12 Years of Age)</u></p><p>Following single dose administration (20 mg/kg) to epileptic children (6 to 12 years of age), the half-life of levetiracetam was 6.0 +/- 1.1 hours. The apparent body clearance was approximately 30% higher than in epileptic adults.</p><p>&nbsp;</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years of age), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately five hours. The apparent body clearance was 1.1 mL/minute/kg.</p><p>&nbsp;</p><p><u>Infants and Children (1 Month to 4 Years of Age)</u></p><p>Following single dose administration (20 mg/kg) of a 10% oral solution to epileptic children (1 month to 4 years of age), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately one hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 hours) than for adults (7.2 hours) and apparent clearance was faster (1.5 mL/minute/kg) than for adults (0.96 mL/minute/kg).</p><p>&nbsp;</p><p><u>Renal Impairment</u></p><p>The apparent body clearance of both levetiracetam and its major metabolite (ucb L057) is correlated to the creatinine clearance. It is, therefore, recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>&nbsp;</p><p>In anuric endstage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively. The fractional removal of levetiracetam was 51% during a typical four hour dialysis session.</p><p>&nbsp;</p><p><u>Hepatic Impairment</u></p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50% due to concomitant renal impairment (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td><p>Copovidone (Kollidon VA64)</p></td></tr><tr><td><p>Colloidal Silicon Dioxide</p></td></tr><tr><td><p>Hypromellose (Hydroxypropyl Methylcellulose 2910 E5)</p></td></tr><tr><td><p>Hydroxypropyl Cellulose Type LF</p></td></tr><tr><td><p>Polyethylene Glycol 8000</p></td></tr><tr><td><p>Titanium Dioxide</p></td></tr><tr><td><p>Yellow Ferric Oxide</p></td></tr><tr><td><p>Citric Acid Anhydrous</p></td></tr><tr><td><p>Iron oxide red</p></td></tr><tr><td><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Store in original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong></p><p>Blister&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plain silver aluminium foil and cold-form silver foil</p><p>&nbsp;</p><p><strong>Secondary packaging:</strong></p><p>Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>